Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


Purpose:

The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.


Study summary:

Allogeneic Peripheral Blood Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia in First Remission or Chronic Myelogenous Leukemia in First Chronic Phase


Criteria:

Inclusion Criteria:1. Any patient with one of the following hematologic malignancies in whom an allogeneic stem cell transplant is warranted: Specific disease categories include: 1. acute myelogenous leukemia, 1st or 2nd remission 2. acute lymphoblastic leukemia, 1st or 2nd remission 3. chronic myelogenous leukemia, 1st or 2nd CP, accelerated phase 2. Patient age > 1 month and < 55 yo 3. Patients must have a genotypically HLA identical sibling 4. Patient must have adequate function as follows: a. total bilirubin <2.5 and SGOT/SGPT <2x normal b. adequate renal function as defined by creatinine < 1.5 or a 24 hr creatinine clearance >50 cc/min as determined by the Cockroft-Gault formula (to be done if serum creatinine > 1.5) c. DLCO > 60% predicted d. radionuclide cardiac scan with ejection fraction >45% 5. Patient must be competent to give consent. Inclusion criteria (Donor): 1. HLA identical family member 2. Donor or guardian must be competent to give consent 3. Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter Exclusion Criteria:3.2 Exclusion Criteria (Patient): 1. Evidence of active infection or active hepatitis 2. Positive serologies for HIV-1,HIV-2 or hepatitis B surface ag+ 3. Previous allogeneic stem cell/bone marrow transplant 4. Pregnant or lactating patients 4 Exclusion criteria (Donor): 1. Donors who for psychologic, physiologic or medical reasons are unable to tolerate PBSC harvest 2. Donors who are HIV+ or hepatitis B antigen + 3. History of allergic reaction to G-CSF 4. Female donors must be post-menopausal or have a negative pregnancy test


NCT ID:

NCT00185523


Primary Contact:

Principal Investigator
Ginna Laport
Stanford University


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.